MetaStat, Inc. (MTST) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mit einem Kurs von $ ist MetaStat, Inc. (MTST) ein Healthcare-Unternehmen mit einer Bewertung von 0. Die Aktie erzielt 57/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 17. März 2026MetaStat, Inc. (MTST) Gesundheitswesen & Pipeline-Uebersicht
MetaStat, Inc. is a biotechnology company focused on precision medicine, developing diagnostics and therapeutics targeting the MENA pathway in cancer. With a small team, MetaStat aims to improve cancer diagnosis and treatment through novel drug candidates and companion diagnostic tests, operating within the competitive biotechnology sector.
Investmentthese
MetaStat, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on the MENA pathway, a key driver of metastasis, offers potential for significant breakthroughs in cancer treatment and diagnostics. However, as a small company with a market capitalization of $0.00 billion and negative profitability (Profit Margin: -13652.5%), MetaStat faces substantial challenges in funding its research and development efforts. The company's success hinges on the successful development and commercialization of its product candidates, including the MENA diagnostic assay and companion diagnostics. Upcoming clinical data and potential partnerships will be critical catalysts. The high beta of 9.69 indicates extreme volatility, reflecting the speculative nature of the investment. Investors should carefully consider the risks associated with early-stage biotechnology companies before investing.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.00B indicates a micro-cap company with high growth potential but also significant risk.
- Profit Margin of -13652.5% reflects the company's current lack of profitability due to heavy investment in R&D.
- Gross Margin of 100.0% suggests that the company's products, once commercialized, have the potential for high profitability.
- Beta of 9.69 indicates extremely high volatility compared to the market, reflecting the speculative nature of the stock.
- Focus on the MENA pathway, a critical metastatic pathway in solid tumors, positions the company at the forefront of cancer research.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary focus on the MENA pathway.
- Development of novel diagnostic assays.
- Expertise in precision medicine for cancer.
- Potential for companion diagnostic partnerships.
Schwaechen
- Limited financial resources.
- Small number of employees.
- Early stage of product development.
- Dependence on successful clinical trials.
Katalysatoren
- Upcoming: Clinical data release from ongoing preclinical studies of therapeutic candidates targeting the MENA pathway.
- Upcoming: Potential partnerships with pharmaceutical companies for companion diagnostic development.
- Ongoing: Continued development and refinement of the MENA diagnostic assay.
- Ongoing: Exploration of new therapeutic applications for the MetaSite Breast assay.
Risiken
- Potential: Failure to obtain regulatory approval for diagnostic assays and therapeutic candidates.
- Potential: Competition from larger biotechnology and pharmaceutical companies.
- Potential: Limited financial resources to fund ongoing research and development.
- Ongoing: High volatility associated with OTC-traded stocks.
- Ongoing: Dependence on successful clinical trials and commercialization efforts.
Wachstumschancen
- MENA Diagnostic Assay Commercialization: MetaStat's MENA diagnostic assay, a tissue-based test, has the potential to significantly improve cancer diagnosis and treatment selection. The market for cancer diagnostics is projected to reach $25 billion by 2028, driven by the increasing demand for personalized medicine. Successful commercialization of this assay, potentially within the next 2-3 years, could generate substantial revenue for MetaStat, especially if it becomes a standard of care for certain cancer types.
- Companion Diagnostic Development: MetaStat is developing companion diagnostics to predict responses to RTK inhibitor drugs and anti-microtubule drugs. The market for companion diagnostics is growing rapidly, driven by the increasing use of targeted therapies in cancer treatment. Partnering with pharmaceutical companies to develop and commercialize these diagnostics could provide MetaStat with a significant revenue stream and enhance its credibility in the industry. This could materialize within the next 3-5 years.
- Liquid Biopsy Technology: MetaStat's development of a liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care represents a significant growth opportunity. The liquid biopsy market is expected to reach $10 billion by 2027, driven by its non-invasive nature and potential for early cancer detection. Successful development and commercialization of this technology could position MetaStat as a leader in the field, potentially within the next 4-6 years.
- MetaSite Breast Assay Expansion: The MetaSite Breast assay, an immunohistochemistry test, offers another avenue for growth. By expanding the clinical applications of this assay and securing partnerships with diagnostic laboratories, MetaStat can increase its market reach and revenue. The breast cancer diagnostics market is substantial, and a successful assay could contribute significantly to MetaStat's growth, potentially within the next 2-4 years.
- Therapeutic Development Targeting MENA Pathway: MetaStat's therapeutic program targeting the MENA pathway represents a long-term growth opportunity. While still in early stages, successful development of a drug that inhibits the MENA pathway could revolutionize cancer treatment. The market for cancer therapeutics is enormous, and a successful drug could generate billions of dollars in revenue. However, this is a high-risk, high-reward endeavor with a timeline of 5-10 years.
Chancen
- Growing market for cancer diagnostics and therapeutics.
- Increasing demand for personalized medicine.
- Potential for partnerships with larger pharmaceutical companies.
- Expansion into new therapeutic areas.
Risiken
- Competition from larger biotechnology and pharmaceutical companies.
- Regulatory hurdles and clinical trial failures.
- Patent challenges and intellectual property disputes.
- Economic downturn affecting healthcare spending.
Wettbewerbsvorteile
- Proprietary technology targeting the MENA pathway.
- Expertise in developing cancer diagnostics and therapeutics.
- Potential for intellectual property protection through patents.
Ueber MTST
MetaStat, Inc., based in Boston, Massachusetts, is a precision medicine company dedicated to discovering and developing innovative therapeutic and diagnostic solutions for cancer patients. The company's primary focus is on targeting the MENA pathway, a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat is developing a range of product candidates, including the MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures the expression of the pro-metastatic MENA protein splice-variant. This assay is intended to predict responses to RTK inhibitor drugs and anti-microtubule drugs. Additionally, MetaStat is working on a liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care, as well as the MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment. The company also aims to develop a prognostic diagnostic to predict the risk of cancer metastasis. MetaStat's therapeutic approach targets this critical metastatic pathway in solid tumors, aiming to overcome tumor resistance and prevent the spread of aggressive cancer.
Was das Unternehmen tut
- Develop diagnostic assays for cancer.
- Create companion diagnostics to predict drug responses.
- Develop liquid blood-based biopsies for cancer diagnosis.
- Research therapeutic targets in the MENA pathway.
- Focus on precision medicine for cancer treatment.
- Develop immunohistochemistry tests for cancer analysis.
Geschaeftsmodell
- Develop and commercialize diagnostic assays for cancer.
- Partner with pharmaceutical companies to develop companion diagnostics.
- Generate revenue through sales of diagnostic products and services.
Branchenkontext
MetaStat, Inc. operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory hurdles. The company focuses on precision medicine, a growing trend in cancer treatment that aims to tailor therapies to individual patients based on their genetic and molecular profiles. The market for cancer diagnostics and therapeutics is substantial and growing, driven by an aging population and increasing incidence of cancer. MetaStat competes with other biotechnology companies, such as ATRX, CDXI, ELOX, LGBI, and MODC, as well as larger pharmaceutical companies that are also developing cancer treatments. The company's success depends on its ability to develop and commercialize innovative products that address unmet needs in cancer care.
Wichtige Kunden
- Hospitals and cancer centers.
- Diagnostic laboratories.
- Pharmaceutical companies.
Finanzdaten
Chart & Info
MetaStat, Inc. (MTST) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Thursday
· 30. Jan. 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer MTST.
Kursziele
Wall-Street-Kurszielanalyse fuer MTST.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von MTST auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Frederick E. Pierce
CEO
Frederick E. Pierce serves as the CEO of MetaStat, Inc., leading a team of six employees. His background includes extensive experience in the biotechnology and pharmaceutical industries. Pierce has held various leadership positions in companies focused on developing and commercializing innovative therapies. His expertise spans areas such as drug development, clinical trials, and regulatory affairs. Pierce's educational background includes advanced degrees in science and business, providing him with a strong foundation for leading a precision medicine company.
Erfolgsbilanz: Under Frederick E. Pierce's leadership, MetaStat, Inc. has focused on advancing its pipeline of diagnostic assays and therapeutic candidates targeting the MENA pathway. Key milestones include the development of the MENA diagnostic assay and the initiation of preclinical studies for novel drug candidates. Pierce has also been instrumental in securing funding and establishing partnerships to support the company's research and development efforts.
MTST OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that MetaStat, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to listed securities.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business plan and market opportunity.
- Evaluate the company's intellectual property and competitive landscape.
- Review the company's capitalization structure and ownership.
- Consult with a qualified financial advisor.
- Understand the risks associated with investing in OTC securities.
- Company is focused on precision medicine for cancer treatment.
- Development of novel diagnostic assays and therapeutic candidates.
- CEO with experience in the biotechnology industry.
- Company based in Boston, a hub for biotechnology innovation.
Haeufige Fragen zu MTST
What are the key factors to evaluate for MTST?
MetaStat, Inc. (MTST) currently holds an AI score of 57/100, indicating moderate score. Key strength: Proprietary focus on the MENA pathway.. Primary risk to monitor: Potential: Failure to obtain regulatory approval for diagnostic assays and therapeutic candidates.. This is not financial advice.
How frequently does MTST data refresh on this page?
MTST prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MTST's recent stock price performance?
Recent price movement in MetaStat, Inc. (MTST) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary focus on the MENA pathway.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MTST overvalued or undervalued right now?
Determining whether MetaStat, Inc. (MTST) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MTST?
Before investing in MetaStat, Inc. (MTST), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding MTST to a portfolio?
Potential reasons to consider MetaStat, Inc. (MTST) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary focus on the MENA pathway.. Additionally: Development of novel diagnostic assays.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of MTST?
Yes, most major brokerages offer fractional shares of MetaStat, Inc. (MTST) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track MTST's earnings and financial reports?
MetaStat, Inc. (MTST) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for MTST earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.
- AI analysis is pending and may provide additional insights.